Proactive Investors - Run By Investors For Investors

Supreme closes mortgage on medical marijuana greenhouse

Company heading into expansion phase for production
Greenhouse growing more product to meet high demand
Greenhouse growing more product to meet high demand

Supreme Pharmaceuticals Inc. (CNSX:SL) just closed a $4 million mortgage with a private lender for a hybrid greenhouse facility in Kincardine, Ontario, the company said on Monday.

Proceeds from the one-year, 12% fixed rate, interest-only mortgage were used to refinance a prior vendor take-back mortgage with respect to its wholly owned subsidiary, 8528934 Canada Ltd. (7 Acres).

Supreme Pharmaceuticals CEO John Fowler explained that this was a significant milestone for the company. "The hybrid greenhouse is exceeding performance expectations with a high-quality first crop nearing harvest in the 16,500-square-foot phase zero, while we expand the production area by 80,000 square feet into phase one."

The greenhouse is dedicated to growing medical-use marijuana and the company has agreements with five licensed producers. After completion of phase one of the project and subject to regulatory approval, Supreme expects total production capacity to rise to over 10,000 kilograms per year.

Supreme Pharma shares were up 2% at C$0.50 in Toronto on Monday.

View full SL profile View Profile

Supreme Pharmaceuticals Timeline

Related Articles

April 17 2019
Driving growth was Lojuxta, used to treat a rare and life-threatening disorder that causes abnormally high levels of bad cholesterol. Its sales grew to €13.6mln, up 14.2% year-on-year
Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
Enzymes under a microscope
April 28 2019
The Florida company applies its proprietary C1 gene expression platform to speed up the development of biologic vaccines, drugs at flexible commercial scales
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use